In a recent study using baicalein to treat UC in DSS-induced mice, it was found that baicalein improved symptoms and intestinal barrier function in mice with colitis by activating AhR, upregulating the expression of cytochrome P4501A1 (CYP1A1), promoting the production of IL-22 in ILC3,and enhancing the levels of tight junction proteins ZO-1 and occludin (85). This evidence concerns the gene IL22 and colitis.